Ahead of ARVO 2025 next week where Emmes is poised to launch the first dedicated ophthalmology clinical trial technology platform, we spoke with Saqib Parkar, Managing Director at Emmes’ OptymEdge, about how CROs can reshape gene therapy trials in ophthalmology. With only one FDA-approved ocular gene therapy on the market, the stakes are high, and timelines are critical. Ophthalmologists working with Saqib emphasise the growing importance of CROs as strategic partners – valued for their transparency, therapeutic expertise, and collaboration.

As cell and gene therapies redefine treatment possibilities, clinicians play a key role in shaping trials that are not only scientifically sound but also tailored to the unique needs of rare disease patients. In this article we explore the pivotal role they play in helping deliver bespoke clinical trials for gene therapies in eye diseases and the profound benefits these trials bring to both practitioners and their patients.